Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Russell M. Medford, T. Forcht Dagi, Robert S. Rosenson, Margaret K. Offermann

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Future innovative therapies targeting cardiovascular disease (CVD) have the potential to improve health outcomes and to contain rising healthcare costs. Unsustainable increases in the size, cost and duration of clinical trial programs necessary for regulatory approval, however, threaten the entire innovation enterprise. Rising costs for clinical trials are due in large part to increasing demands for hard cardiovascular clinical endpoints as measures of therapeutic efficacy. The development and validation of predictive and surrogate biomarkers, as laboratory or other objective measures predictive or reflective of clinical endpoints, are an important part of the solution to this challenge. This review will discuss insights applicable to CVD derived from the use of predictive biomarkers in oncologic drug development, the evolving role of high density lipoprotein (HDL) in CVD drug development and the impact biomarkers and surrogates have on the continued investment from multiple societal sources critical for innovative CVD drug discovery and development.

Original languageEnglish
Article number321
JournalUnknown Journal
Volume15
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Dive into the research topics of 'Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.'. Together they form a unique fingerprint.

Cite this